Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000875320-26-000173
FAQ
- What is Vertex Pharmaceuticals's AOCI?
- Vertex Pharmaceuticals (VRTX) reported AOCI of $24.8M in Q1 2026.
- How has Vertex Pharmaceuticals's AOCI changed year-over-year?
- Vertex Pharmaceuticals's AOCI decreased by 63.6% year-over-year, from $68.1M to $24.8M.
- What is the long-term trend for Vertex Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's AOCI has grown at a -25.3% compound annual growth rate (CAGR), from -$68.5M to -$15.9M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Vertex Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude